Table 2

Primary and secondary outcomes for patients with SLE/APS in both cohorts

Pregnancies (n)SLE
(±secondary APS)
Primary APS
(thrombotic+obstetric)
Pathway
N=16
Historical
N=43
Pathway
N=25
Historical
N=28
Disease outcomes
SLE flare2 (12.5)17 (39.5)
 Major SLE flare1 (6.3)7 (16.3)
  Kidney0/1 (0.0)6/7 (85.7)
  Heart/Lungs1/1 (100.0)0/7 (0.0)
  Nervous system0/1 (0.0)0/7 (0.0)
  Haematological0/1 (0.0)2/7 (28.6)
 Minor SLE flare1 (6.3)10 (23.3)
  Joints1/1 (100.0)8/10 (80.0)
  Skin0/1 (0.0)4/10 (40.0)
SLEPDAI*7 (6–8)4 (2–16)
Thromboembolic events0 (0.0)0 (0.0)1 (4.0)3 (10.7)
Maternal outcomes
Miscarriage0 (0.0)3 (7.0)10 (40.0)14 (50.0)
 <10 weeks0 (0.0)3 (7.0)10 (40.0)9 (32.1)
 10–16 weeks0 (0.0)0 (0.0)0 (0.0)5 (17.9)
Gestational hypertension†1 (6.3)2 (5.0)2 (13.3)0 (0.0)
Severe hypertensive disease†5 (31.3)13 (32.5)4 (26.7)4 (28.6)
Vaginal delivery†11 (68.8)25 (62.5)7 (46.7)9 (64.3)
Fetal outcomes
Perinatal death†1 (6.3)1 (2.5)0 (0.0)0 (0.0)
FGR (EFW <p10)†3 (18.8)8 (20.0)1 (6.7)1 (7.1)
Preterm birth <37 weeks†6 (37.5)15 (37.5)6 (40.0)3 (21.4)
Preterm birth <32 weeks†1 (6.3)5 (12.5)1 (6.7)2 (14.3)
Congenital heart block†0 (0.0)1 (2.5)0 (0.0)0 (0.0)
NICU admission†2 (12.5)7 (17.5)1 (6.7)2 (14.3)
  • Data depicted as number of pregnancies (% of cohort).

  • Severe hypertensive disease=pre-eclampsia, eclampsia or HELLP.

  • *Median (minimum, maximum).

  • †For calculations miscarriages were excluded.

  • APS, antiphospholipid syndrome; EFW, estimated fetal weight; FGR, fetal growth restriction; HELLP, haemolysis elevated liver enzymes low platelets; NICU, neonatal intensive care unit; ; SLEPDAI, Systemic Lupus Erythematosus Pregnancy Disease Activity Index.